# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001764013-22-000068
Filing Date
2022-06-30
Accepted
2022-06-30 07:15:07
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | defa14acoverpage-3x31x22.htm | DEFA14A | 11862
2 | GRAPHIC | immunovantinc_vsmvxnaxp747a.jpg | GRAPHIC | 489617
3 | GRAPHIC | immunovantinc_vsmvxnaxp747.jpg | GRAPHIC | 349923
| Complete submission text file | 0001764013-22-000068.txt |  | 1168880

Mailing Address 320 WEST 37TH STREET NEW YORK NY 10018
Business Address 320 WEST 37TH STREET NEW YORK NY 10018 917-580-3099
Immunovant, Inc. (Filer) CIK: 0001764013 (see all company filings)

EIN.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
Type: DEFA14A | Act: 34 | File No.: 001-38906 | Film No.: 221056493
SIC: 2836 Biological Products, (No Diagnostic Substances)